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Abstract
Background: In the U.S. more than half of incident tuberculosis (TB) cases occur in immigrants.
Current guidelines recommend screening and treatment for latent TB infection (LTBI) within 5
years of arrival to the U.S. This study evaluates the timing of LTBI therapy among immigrants
presenting for care to a public health TB clinic.
Methods: Retrospective chart review of patients prescribed LTBI treatment based on medical
records from Prince Georges County Health Department.
Results: 1882 immigrants received LTBI therapy at Prince Georges County Health Department
between 1999 and 2004. 417 of these patients were diagnosed with LTBI through contact
investigations and were excluded from the analysis. Among the remaining 1465 individuals, median
time from arrival to the U.S. until initiation of LTBI therapy was 5 months (range 0–42.4 years).
16% of all immigrants initiated therapy more than 5 years after arrival to the U.S. A logistic
regression model using risks identified on univariate analysis revealed that referral for therapy by
non-immigration proceedings was the strongest predictor of initiation of therapy more than 5 years
after arrival to the U.S. Other factors associated with > 5 year U.S. residence prior to initiation of
LTBI therapy included female gender (adjusted odds ratio (AOR) 1.8, 95% CI 1.2–2.6), age ≥ 35
(AOR = 4.1, 95% 2.5–6.6), and originating from Latin American and the Caribbean (AOR = 1.9, 95%
CI 1.3–3.0).
Conclusion: Foreign-born individuals who are not referred for LTBI therapy through immigration
proceedings are less likely to receive LTBI therapy within 5 years of arrival to the U.S. These data
highlight the need to explore other mechanisms for timely LTBI screening beyond services
provided by immigration.
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Background
Tuberculosis (TB) case rates in the United States have
declined since 1993, but the decline among foreign-born
persons has been less substantial than that among indi-
viduals born in the U.S.[1] Each year since 2002, more
than half of incident TB cases in the U.S. occurred among
foreign-born individuals[1]. In order to accelerate the
decline of TB in the U.S., the Institute of Medicine has
emphasized the need to identify and treat individuals
with latent TB infection (LTBI), including the need for
screening of immigrants from countries with high TB
rates[2]. A key component of the U.S. TB elimination
strategy is the identification and treatment of foreign-born
individuals at high risk for TB [3,4]. Current U.S. immigra-
tion laws require screening persons older than 14 years
old for active TB with a chest radiograph during the appli-
cation for immigrant visas prior to entry to the U.S. Indi-
viduals with abnormal radiographs suggestive of TB have
three sputum smears evaluated for the presence of acid
fast bacilli. Immigrants with abnormal radiographs but
no evidence of active TB are able to travel to the U.S. but
are required to report to a local health department for fur-
ther evaluation within 30 days of arrival to the U.S. Many
of these patients are found to be candidates for LTBI ther-
apy[5]. Screening for LTBI with the tuberculin skin test is
also required for immigrants already residing in the U.S.
who apply for adjustment of immigrant status to perma-
nent residents (Code of Federal Regulations, Title 42)
[6,7].
Therefore, LTBI screening among foreign-born popula-
tions targets individuals at high risk of TB applying for
entry visas to the U.S. or immigrants already residing in
the U.S. applying for permanent residency. This strategy
facilitates prompt recognition of TB disease in some
classes of documented immigrants at risk for TB [5,8-10],
but does not address the needs of people from TB
endemic areas who enter the U.S. without documentation
or who overstay tourist visas and do not apply for status
change [3,10]. Screening and treatment for latent infec-
tion are recommended for all foreign-born persons who
have resided in the U.S. for up to 5 years [3,11], since the
highest rates of active disease occur in this group.
Although the risk of active TB among foreign-born indi-
viduals who have lived in the U.S. for more than 5 years is
lower than in recent arrivals, rates in this population are
significantly higher than in U.S. born individuals[12].
Because LTBI is asymptomatic and screening programs are
uncommon outside the U.S., individuals at high risk for
TB who are not screened through immigration proceed-
ings may not seek LTBI testing on their own. A key ques-
tion for TB control is how to expand timely LTBI screening
programs for this population. In this study, we evaluate
the characteristics of foreign-born patients presenting to a
public health clinic for LTBI therapy and the timing of
presentation relative to the time of arrival to the U.S.
Characterization of patients that initiate therapy can iden-
tify successful interventions and provide an insight into
strategies that require further attention.
Methods
We performed a retrospective study of all foreign-born
individuals treated for LTBI during the period of January
1, 1999 to January 31, 2004 at the Prince Georges County
Health Department in Maryland using an existing data-
base[13]. In brief, a list of all patients who were treated for
LTBI during the study period was obtained from a compu-
terized registration database maintained by the TB control
program. Information was obtained by medical record
review, abstracted onto a data form, and entered into a
study database. We also obtained non-identified informa-
tion from the registration database regarding the country
of origin of patients receiving LTBI therapy from 1990–
2004. Institutional review boards of Johns Hopkins Uni-
versity School of Medicine and Maryland Department of
Health and Mental Hygiene approved this study.
Data obtained included: gender, age, self-identified race/
ethnicity, country of origin, date of U.S. arrival, date of
first clinic visit, reason for LTBI therapy, source of referral,
prescribed LTBI treatment regimen, tuberculin skin test
size, prescribing clinician, adverse drug reactions, comple-
tion of therapy, and HIV serostatus. For analytical pur-
poses, two age categories (≤ 35, > 35 years), and four race/
ethnicity categories (White non-Hispanic, Black non-His-
panic, Hispanic & Asia/Other) were used. Native Hawai-
ians and Pacific Islanders were included in the Asia/Other
category due to low numbers (n = 5). The four categories
for region of origin (Europe & Canada, Latin America &
the Caribbean, Africa, and Asia) were derived from coun-
try of origin data and were chosen to reflect regional sim-
ilarities in the risk of tuberculosis and immigration
patterns. Source of referral was categorized into Immigra-
tion, Primary Medical Doctor, and Other (self-referrals
and walk-ins).
All persons with LTBI referred for treatment and not
known to have recent contact with an infectious TB case
were assumed to have been infected in their countries of
origin. The primary outcome was duration of time
between arrival to the U.S. and initiation of LTBI therapy.
This outcome was calculated by subtracting the date of
first visit to the clinic from self-reported date of arrival to
the U.S. and categorized into 3 groups (< 1 year, 1–5 years
and > 5 years) for analysis. "LTBI therapy delay" was
defined as LTBI initiated > 5 years after arrival since cur-
rent LTBI screening and treatment guidelines do not target
immigrants who have lived in the U.S. more than 5 years
[11].BMC Public Health 2008, 8:158 http://www.biomedcentral.com/1471-2458/8/158
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Univariate associations between predictors and time to
referral were examined using Chi square for categorical
variables (gender, age category, race/ethnicity, region of
origin, reason for LTBI therapy, HIV serostatus, source of
referral), and Wilcoxon rank-sum test for non-normally
distributed continuous variables (age, TST size). Univari-
ate predictors showing a statistical association with delay
(p < 0.05) were entered into the multivariate model. The
final model was derived by removing insignificant (p >
0.05) variables as determined by the likelihood ratio test.
Race/ethnicity was removed from the final model due to
collinearity with region of origin, as measured by the var-
iance inflation factor. Adjusted odds ratios (AOR) and
corresponding 95% confidence intervals (95% CI) were
calculated for the variables that remained in the final
model. Analyses were performed using STATA Statistical
Software (Stata Corp: Stata Statistical Software: Release
8.0, Stata Corporation, College Station, TX, 2002).
Results
Baseline characteristics of the study population
A total of 1882 foreign-born patients were offered LTBI
therapy at Prince George's County TB clinic from January
1, 1999 to January 21, 2004. In order to minimize the pos-
sibility of including individuals infected with TB after
arrival to the US, we excluded 417 individuals who were
diagnosed with LTBI during a contact investigation
because we could not rule out the possibility of recently
acquired infection. In addition, 3 patients had incomplete
data and were excluded from the final multivariate model
which included 1463 patients. Baseline characteristics of
the study population are shown in Table 1. The cohort
was relatively young (median age 23 yrs, interquartile
range or IQR = 15–32) with a slight female predominance
(54%). The vast majority of patients (n = 1406, 96%) orig-
inated from one of 3 regions: Africa (n = 839, 57%), Latin
America & the Caribbean (n = 414, 28%), and Asia (n =
153, 11%). Relatively few patients were born in Europe &
Canada (n = 53, 4%). Racial and ethnic distribution mim-
icked the distributions of the region of origin. Among
patients tested for HIV (n = 508), few were HIV seroposi-
tive (n = 10, 2%). Of the patients with unknown HIV sta-
tus (n = 957), one fifth (n = 180, 19%) refused HIV
testing, and the remainder (n = 777, 81%) had no docu-
mentation of HIV counseling or testing. A greater propor-
tion of patients from Latin America & the Caribbean
(92%) or Asia (66%) had an unknown HIV serostatus
compared to patients from Africa (54%) or Europe & Can-
Table 1: Baseline characteristics according to length of U.S. residence at initial visit for LTBI therapy
Length of U.S. Residence
Total (n, %) Median Time in Months (IQR) < 1 year (n, %) 1–5 years (n, %) > 5 years (n, %) p value
Total 1465 5 (2–30) 899 (61.4) 336 (22.9) 230 (15.7)
Gender
Male 673 (46.0) 4 (2–24) 448 (66.6) 140 (20.8) 85 (12.6) < 0.001
Female 789 (54.0) 7 (0.2–77) 449 (59.9) 195 (24.7) 145 (18.4)
Age
Median (IQR) 23 (15–32) 20 (14–30) 24 (17–32) 30 (24–36) < 0.001
< 35 yrs 1180 (80.6) 5 (2–28) 741 (62.8) 277 (23.5) 162 (13.7)
≥ 35 yrs 285 (19.5) 5 (2–54) 158 (55.4) 59 (20.7) 68 (23.9)
Region of Origin
Africa 839 (57.4) 4 (2–14) 604 (72.0) 170 (20.3) 65 (7.8) < 0.001
Latin America & Caribbean 414 (28.3) 28 (6–79) 140 (33.8) 138 (33.3) 136 (32.9)
Asia 153 (10.7) 4 (2–26) 102 (66.7) 24 (15.7) 27 (17.7)
Canada & Europe 56 (3.8) 2 (1–4) 51 (91.1) 3 (5.4) 2 (3.6)
Race/Ethnicity
White 59 (4.0) 2 (1–4) 53 (89.8) 4 (6.8) 2 (3.4) < 0.001
Hispanic 352 (24.1) 25 (6–72) 129 (36.7) 119 (33.8) 104 (29.6)
Black 876 (59.9) 4 (2–18) 603 (68.8) 180 (20.6) 93 (10.6)
Other 175 (12.0) 4 (2–170) 113 (64.6) 32 (18.2) 30 (17.1)
TST size (mm)
Size (IQR) 15 (12–20) 15 (12–19) 15 (13–20) 16 (14–20) 0.67
HIV status
Negative 498 (34.0) 2 (1–4) 440 (88.3) 30 (6.0) 28 (5.6) < 0.001
Positive 10 (0.7) 10 (4–16) 5 (50.0) 3 (30.0) 2 (20.0)
Unknown 957 (65.3) 13 (4–49) 454 (47.4) 303 (31.7) 200 (20.9)
Referral
Immigration 666 (46) 2 (1–4) 638 (95.8) 24 (3.6) 4 (0.6) < 0.001
Primary Medical Doctor 121 (8.4) 35 (12–90) 28 (23.1) 48 (39.7) 45 (37.2)
Other* 662 (45.7) 24 (7–64) 226 (34.1) 259 (39.1) 177 (26.7)
* Other = self-referrals, walk-in patientsBMC Public Health 2008, 8:158 http://www.biomedcentral.com/1471-2458/8/158
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ada (30%, p = 0.001). However, refusal of HIV testing was
not associated with region of origin (Chi square, p =
0.96).
Time to initiation of LTBI therapy after arrival to the U.S
Table 1 shows the period of residence in the U.S. in years
at initiation of LTBI therapy according to baseline patient
characteristics. The median time from arrival to the U.S.
until LTBI therapy was 5 months (IQR range 2–30
months). In accordance to guidelines targeting recent
arrivals to the U.S., the majority of patients received LTBI
therapy within 5 years of arrival to the U.S. (n = 1235,
84%); 16% of the patients had been in the U.S. for over 5
years prior to receiving LTBI therapy (n = 230).
Univariate analysis identified the following risk factors for
initiation of LTBI therapy more than five years after arrival
to the U.S.: age, gender, region of origin, race/ethnicity,
HIV status, and source of referral (Table 1). In multivariate
analysis adjusting for gender, age, region of origin, HIV
serostatus, and source of referral we identified source of
referral as the major predictor for delays in LTBI therapy
(Table 2). Patients who were not referred for LTBI therapy
through immigration proceedings had a very high risk of
receiving LTBI therapy more than 5 years after arrival to
the U.S. More than one third of patients referred for LTBI
therapy by their primary medical doctor (PMD) received
therapy 5 years after arrival to the U.S. (AOR = 251.7, 95%
CI 78.4–808.2), and over one fourth of patients who self-
referred or walked-in to the TB clinic received LTBI ther-
apy 5 years after arrival (AOR = 113.7, 95% CI 38.5–
335.6). Other risk factors for delayed LTBI therapy
included female gender (AOR = 1.80, 95% C.I. 1.24–
2.60), age > 35 years old (AOR = 4.11, 95% C.I. 2.54–
6.64), and originating from Latin America and the Carib-
bean (AOR = 1.95, 95% C.I. 1.28–2.95)
Given the strong association between timing of LTBI ther-
apy and source of referral, we stratified source of referral
by region of origin, age, and gender. Figure 1 shows that
more than half of the patients from Africa (63%), Asia
(53%), and Europe and Canada (89%) were referred
through immigration proceeding related to applications
for refugees, immigrants, and status adjustment, com-
pared to only 3% of patients from Latin America and the
Caribbean. Eleven percent of patients from Latin America
& the Caribbean were referred by their primary medical
doctor (PMD), but over 80% of patients from this region
self-referred or walked-in to the clinic. Univariate analysis
showed that fewer women than men (43% vs. 50%, Chi
square p = 0.016) were referred to LTBI therapy by immi-
gration services, but there was no significant association
between age and source of referral (Chi square p = 0.41).
Multivariate analysis adjusting for age, gender, and region
of origin showed that region of origin was the only factor
independently associated with referral by immigration
proceedings (Table 3).
Regional distribution and source of referral for patients 
treated for LTBI at Prince George's County Health 
Department
In order to determine whether the regional differences in
time to initiation of LTBI therapy after arrival to the U.S.
could be due to a cohort effect, we obtained non-identi-
fied information regarding region of origin from the com-
puterized registration database for all foreign-born
individuals treated for LTBI from 1990–2004. Figure 2
shows the proportion of immigrants from Asia, Africa,
Latin America & the Caribbean, and Europe & Canada
who received LTBI therapy at Prince Georges County since
1990. These data suggest that immigration to Prince
Georges County from all regions began more than 5 years
Table 2: Factors associated with initiation of LTBI therapy more 
than 5 years after arrival to the U.S.
Length of U.S. Residence
1 – 5 years > 5 years
AOR* (95% CI) AOR* (95% CI)
Gender
Male Reference
Female 1.3 (1.0–1.8) 1.8 (1.2–2.6)
Age
< 35 Reference
≥ 35 1.9 (1.2–3.0) 4.1 (2.5–6.6)
Region of Origin
Africa Reference Reference
Latin America & 
Caribbean
0.7 (0.5–1.0) 1.9 (1.3–3.0)
Asia 0.6 (0.3–1.0) 1.7 (0.9–3.2)
Canada & Europe 0.6 (0.1–2.4) 1.4 (0.2–7.5)
HIV Status
Negative Reference
Positive 1.2 (0.2–5.7) 0.6 (0.1–3.5)
Unknown 2.4 (1.5–4.0) 1.1 (0.6–1.9)
Referral
Immigration Reference Reference
Primary Medical 
Doctor
38.3 (19.6–74.6) 251.7 (78.4–808.2)
Other** 24.8 (14.9–41.2) 113.7 (38.5–335.6)
Abbreviations: AOR adjusted odds ratio, CI = confidence interval 
AOR obtained after adjustment for gender, age, region of origin, and 
HIV status
* Reference category for outcome is < 1 year
** Other = self-referrals, walk-in patientsBMC Public Health 2008, 8:158 http://www.biomedcentral.com/1471-2458/8/158
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prior to our dates of inclusion in our database (1998–
2004).
Discussion
In this retrospective study of 1465 foreign-born individu-
als receiving LTBI therapy at a public TB clinic, we found
that referral through immigration proceedings was the
strongest predictor of timely initiation of LTBI therapy. In
fact, 99.4% of patients referred by immigration proceed-
ings received LTBI therapy within 5 years of arrival to the
U.S. as recommended by current guidelines [11]. These
findings are not surprising given the close link between TB
control programs and immigration proceedings. How-
ever, a significant proportion of foreign-born individuals
in the U.S. never seeks entry visas and may not have access
to immigration-based LTBI screening programs. It is esti-
mated that over 25% of immigrants currently living in the
U.S. are undocumented and are not in a position to apply
for permanent residency status [14].
In our study, over 50% of patients were not referred
through immigration proceedings. These patients were at
high risk for receiving LTBI therapy more than 5 years after
arrival to the U.S. This finding is concerning because
guidelines published in 2000 by the Centers of Disease
Control and Prevention (CDC) and the American Tho-
racic society recommend testing and treating only foreign-
born persons who have been in the U.S. for 5 years or
less[11]. However, immigrants have a high risk of TB even
after living in the U.S. for more than 5 years and would
likely benefit from LTBI therapy. In 2004, almost one
quarter (24%) of all cases of TB in the U.S. occurred
among immigrants who had arrived to the U.S. more than
5 years previously[12]. Over 50% of TB cases in Mexican-
born individuals occurs after prolonged (> 5 years) dura-
tion of residence in the U.S.[15] Furthermore, DNA fin-
gerprinting analysis of M. tuberculosis isolated from TB
cases in foreign-born patients shows nonclustering, sug-
gesting that most cases are due to reactivation of infection
acquired in their country of origin[16,17]. These data sug-
gest that timely diagnosis of LTBI has the potential to pre-
vent most cases of active TB disease among immigrants
who comply with therapy[18]. Adherence to LTBI therapy
is almost twice as high among individuals from Latin
America, the Caribbean and Asia compared to US-born
individuals[13].
Other factors associated with delays in LTBI therapy
included older age, female gender, and originating from
Latin America and the Caribbean. Delays in adults older
than 35 years might reflect previous guidelines which did
not recommend LTBI therapy for patients older than 35
Table 3: Factors associated with source of referral
Immigration n, % PMD n, % Other n, % AOR*
Total 666 (46.0) 121 (8.4) 662 (45.7)
Gender
Male 334 (50.0) 55 (8.2) 279 (41.8) Reference
Female 332 (42.7) 65 (8.4) 381 (49.0) 0.9 (0.6–1.4)
Age
< 35 yrs 527 (45.1) 97 (8.3) 543 (46.5) Reference
≥ 35 yrs 139 (49.3) 24 (8.5) 119 (42.2) 1.4 (0.8–2.5)
Region of Origin
Africa 524 (63.1) 50 (6.0) 256 (30.8) Reference
Latin America & Caribbean 12 (2.9) 47 (11.5) 350 (85.6) 0.02 (0.01–0.05)
Asia 80 (53.0) 22 (14.6) 49 (32.4) 0.3 (0.2–0.6)
Canada & Europe 50 (89.3) 2 (3.6) 4 (7.1) 2.3 (0.6–9.9)
AOR = Adjusted odds ratio for referral through immigration proceedings
Complete data available for 1443 individuals
Source of referral for LTBI therapy in our study cohort  according to region of origin, Prince Georges County Health  Department, Maryland, 1999–2004 Figure 1
Source of referral for LTBI therapy in our study 
cohort according to region of origin, Prince Georges 
County Health Department, Maryland, 1999–2004. 
Abbreviation: PMD = Primary Medical Doctor. Immigration = 
Referral from the U.S. Citizenship and Immigration Services 
following medical evaluation for refugees, immigrants, and 
status adjustment.
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years, discouraging LTBI testing in this age group[19].
However, this finding is subject to bias or cohort effect
since younger immigrants are less likely to have been in
the U.S. for > 5 years. Our dataset did not allow us to dis-
cern why females may be at higher risk for delays in LTBI
therapy, though gender inequalities have been docu-
mented for other preventive services. Although fewer
women were referred by immigration proceedings, gender
was not independently associated with referral mode.
Almost one third of patients from Latin America and the
Caribbean received LTBI therapy more than 5 years after
arrival to the U.S. These findings are concerning given that
in 2005 69% of all TB cases among foreign-born people in
the U.S. occurred among individuals from Latin America
and the Caribbean [20]. As in other immigrant groups,
timing of LTBI therapy in this population was mostly
influenced by referral mode since only 3% of patients
from Latin America and the Caribbean were referred
through immigration services. However, our data did not
allow us to explore other independent risk factors associ-
ated with delays in LTBI therapy in this group.
Because our data were limited to patients who presented
to the clinic for LTBI therapy, we could not evaluate the
characteristics of immigrants who never access LTBI
screening or therapy. Nonetheless, our findings provide a
basis for future studies exploring other strategies for
timely LTBI screening and therapy in this crucial popula-
tion for TB control. Over 50% of the patients in our cohort
were self-referred or referred by their PMD, highlighting
the importance of developing LTBI programs beyond
immigration service proceedings. Self-referrals and walk-
ins were an important method of entry to the clinic, sug-
gesting the increased awareness of public TB services at the
community level may facilitate access to LTBI screening
and therapy. Research is needed to identify factors associ-
ated with self-referral, such as personal acquaintances
(word-of-mouth), educational programs, work-related
requirements, or informational brochures. Raising aware-
ness of LTBI screening among the medical community
may also enhance timely referral for therapy in high risk
populations. However, delayed referrals by primary med-
ical providers may reflect poor access to general medical
care in immigrant populations. Our data suggests that
expansion of LTBI screening and treatment to include for-
eign-born individuals who have lived in the U.S. for more
than 5 years may be one way to enhance TB control pro-
grams.
There are several limitations to our study. In estimating
delays in initiation of LTBI therapy, we assumed that most
LTBI infection in immigrants was acquired in the country
of origin. However, epidemiologic clustering of active
cases among immigrants from the same region may lead
to ongoing exposure to TB after arrival in the U.S. We
removed individuals identified through contact investiga-
tions to minimize the chance of including patients
infected with TB after arrival to the U.S. Furthermore,
despite the relatively large size of our patient population,
our study was limited to one county TB control program
Regional Distribution of Foreign-born Individuals Receiving LTBI Therapy at Prince Georges County Health Department, Mar- yland, 1990–2004 Figure 2
Regional Distribution of Foreign-born Individuals Receiving LTBI Therapy at Prince Georges County Health 
Department, Maryland, 1990–2004.
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in Maryland. The generalizability of our results to the total
U.S. immigrant population depends on local immigration
patterns and health care delivery strategies for foreign-
born individuals.
Conclusion
The CDC is considering several strategies to address the
high rate of TB among foreign born individuals in the
U.S., such as revising medical screening for applicants for
U.S. immigration, and working with international organ-
izations to reduce TB in the countries of origin[1]. These
strategies should decrease the importation of new TB cases
from other countries, but do not address the risk of TB in
foreign-born individuals who already reside in the U.S.,
especially among undocumented immigrants who are not
routinely screened at entry to the country. Our study
shows that immigrants who are not referred by immigra-
tion proceedings have a high risk of presenting for LTBI
therapy more than 5 years after arrival to the U.S. These
data highlight the need for strategies beyond immigra-
tion-linked programs to identify and overcome missed
opportunities for LTBI therapy among high risk foreign-
born individuals, including those who have lived the U.S.
for > 5 years.
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